SAB Biotherapeutics, Inc.
SABS
$1.79
$0.03992.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -62.39% | -- | 207.72% | 62.55% | -85.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -62.39% | -- | 207.72% | 62.55% | -85.89% |
| Cost of Revenue | 78.05% | 94.81% | 86.29% | 79.60% | -39.80% |
| Gross Profit | -88.78% | -184.50% | -83.39% | -82.10% | 19.79% |
| SG&A Expenses | -83.39% | 35.32% | 25.61% | 21.51% | 416.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.22% | 71.61% | 59.47% | 54.52% | 91.39% |
| Operating Income | 46.97% | -112.47% | -57.52% | -53.89% | -140.12% |
| Income Before Tax | 50.15% | -102.84% | -6.61% | 31.66% | -191.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.15% | -102.84% | -6.61% | 31.66% | -190.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.15% | -102.84% | -6.61% | 31.66% | -190.26% |
| EBIT | 46.97% | -112.47% | -57.52% | -53.89% | -140.12% |
| EBITDA | 48.50% | -137.74% | -63.49% | -44.96% | -157.88% |
| EPS Basic | 63.73% | -14.80% | 41.92% | 62.73% | -93.08% |
| Normalized Basic EPS | 63.65% | -14.81% | 41.92% | 62.73% | -92.54% |
| EPS Diluted | 63.73% | -14.80% | 41.92% | 62.73% | -93.08% |
| Normalized Diluted EPS | 63.65% | -14.81% | 41.92% | 62.73% | -92.54% |
| Average Basic Shares Outstanding | 37.43% | 76.68% | 83.55% | 83.38% | 50.33% |
| Average Diluted Shares Outstanding | 37.43% | 76.68% | 83.55% | 83.38% | 50.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |